Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

News & Events

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 17 April 2020

    ORYZON provides a corporate update in the context of COVID-19

  • 17 April 2020

    ORYZON appoints Eisai executive Vanessa Almendro Navarro to Board of Directors

  • 3 April 2020

    ORYZON presents efficacy data from its two vafidemstat clinical trials in Alzheimer’s disease at the virtual AAT-AD/PD 2020 Conference

  • 28 February 2020

    ORYZON committed to rare diseases with its research in acute myeloid leukemia

  • 24 February 2020

    ORYZON Reports Financial Results and Corporate Update for the 4thQuarter and Year Ended December 31, 2019

  • 27 January 2020

    ORYZON to present at upcoming international conferences

  • 8 January 2020

    ORYZON to present at the 3rd Neuroscience Innovation Forum in San Francisco

  • 9 December 2019

    ORYZON presents new efficacy data from its Phase II trial ALICE investigating iadademstat in AML

  • 2 December 2019

    ORYZON to present at upcoming international conferences

  • 11 November 2019

    ORYZON to present at upcoming international conferences

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 19
  • Page 20
  • Current page 21
  • Page 22
  • Page 23
  • Page 24
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe
Oryzon Extraordinary General Meeting of Shareholders, 15 December 2026Oryzon Extraordinary General Meeting of Shareholders, 15 December 2026
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel